PDCD1 and dermatitis: Furthermore, immune-related adverse events of any grade were observed in 13 (28.3%) patients, including hepatitis, dermatitis, and hypothyroidism, which were associated with PD-1 inhibitors as reported in the previous studies (34, 35).